Should I Buy INM? INM 2026 Analysis

Should You Buy InMed Pharmaceuticals Inc (INM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.100

1 Day change

52 Week Range

7.980

Analysis Updated At

2026/01/29

InMed Pharmaceuticals Inc (INM) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows no significant positive momentum, lacks strong trading signals, and has weak financial performance. It is better to hold off on investing until more favorable conditions arise.

Technical Analysis

The technical indicators show mixed signals. The MACD is positive and expanding, which is a slight bullish indicator. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point of 1.098, with resistance levels at 1.156 and 1.191, and support levels at 1.041 and 1.006. Overall, the trend does not suggest a strong buying opportunity.

Options Data

Positive Catalysts

The MACD is positively expanding, and the gross margin has slightly improved YoY.

Neutral/Negative Catalysts

Revenue dropped by 11.43% YoY, EPS declined significantly by 99.19% YoY, and there is no recent news or significant trading activity from insiders or hedge funds. Additionally, the stock has a low market cap of $3.06M, indicating higher risk.

Financial Performance

In Q1 2026, revenue decreased by 11.43% YoY to $1,120,121. Net income improved slightly but remains negative at -$1,726,899. EPS dropped significantly by 99.19% YoY to -0.44. Gross margin increased marginally to 31.24%, up 2.83% YoY. Overall, the financials indicate weak performance.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes are available for this stock.

Analyst Rating

Wall Street analysts forecast INM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INM is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 1.100

Low

Averages

High